These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 8960733)

  • 1. Liquid levodopa/carbidopa produces significant improvement in motor function without dyskinesia exacerbation.
    Pappert EJ; Goetz CG; Niederman F; Ling ZD; Stebbins GT; Carvey PM
    Neurology; 1996 Dec; 47(6):1493-5. PubMed ID: 8960733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
    Hinson VK; Goetz CG; Leurgans S; Fan W; Nguyen T; Hsu A
    Clin Neuropharmacol; 2009; 32(4):189-92. PubMed ID: 19620848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa.
    Metman LV; Hoff J; Mouradian MM; Chase TN
    Mov Disord; 1994 Jul; 9(4):463-5. PubMed ID: 7969216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamics, Efficacy, and Safety of IPX203 in Parkinson Disease Patients With Motor Fluctuations.
    Modi NB; Mittur A; Dinh P; Rubens R; Gupta S
    Clin Neuropharmacol; 2019; 42(5):149-156. PubMed ID: 31306216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial.
    Hauser RA; Hsu A; Kell S; Espay AJ; Sethi K; Stacy M; Ondo W; O'Connell M; Gupta S;
    Lancet Neurol; 2013 Apr; 12(4):346-56. PubMed ID: 23485610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Concomitant Medications on the Safety and Efficacy of Extended-Release Carbidopa-Levodopa (IPX066) in Patients With Advanced Parkinson Disease: A Post Hoc Analysis.
    LeWitt PA; Verhagen Metman L; Rubens R; Khanna S; Kell S; Gupta S
    Clin Neuropharmacol; 2018; 41(2):47-55. PubMed ID: 29432286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conversion to IPX066 from Standard Levodopa Formulations in Advanced Parkinson's Disease: Experience in Clinical Trials.
    Nausieda PA; Hsu A; Elmer L; Gil RA; Spiegel J; Singer C; Khanna S; Rubens R; Kell S; Modi NB; Gupta S
    J Parkinsons Dis; 2015; 5(4):837-45. PubMed ID: 26444090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral levodopa/carbidopa solution versus tablets in Parkinson's patients with severe fluctuations: a pilot study.
    Kurth MC; Tetrud JW; Irwin I; Lyness WH; Langston JW
    Neurology; 1993 May; 43(5):1036-9. PubMed ID: 8492922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease.
    Müller T; Ander L; Kolf K; Woitalla D; Muhlack S
    J Neural Transm (Vienna); 2007; 114(11):1457-62. PubMed ID: 17564755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacodynamics of IPX066: an oral extended-release capsule formulation of carbidopa-levodopa, and immediate-release carbidopa-levodopa in patients with advanced Parkinson's disease.
    Mao Z; Hsu A; Gupta S; Modi NB
    J Clin Pharmacol; 2013 May; 53(5):523-31. PubMed ID: 23426902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Transitional Probability Model for Parkinson's Disease Motor States With Applications to Missing Data.
    Dinh P
    Ther Innov Regul Sci; 2019 Jul; 53(4):420-425. PubMed ID: 30226796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients.
    Antonini A; Fung VS; Boyd JT; Slevin JT; Hall C; Chatamra K; Eaton S; Benesh JA
    Mov Disord; 2016 Apr; 31(4):530-7. PubMed ID: 26817533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
    Nyholm D; Nilsson Remahl AI; Dizdar N; Constantinescu R; Holmberg B; Jansson R; Aquilonius SM; Askmark H
    Neurology; 2005 Jan; 64(2):216-23. PubMed ID: 15668416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of IPX066 , an extended release carbidopa-levodopa formulation, for the treatment of Parkinson's disease.
    Kestenbaum M; Fahn S
    Expert Opin Drug Saf; 2015 May; 14(5):761-7. PubMed ID: 25697185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients.
    Stocchi F; Hsu A; Khanna S; Ellenbogen A; Mahler A; Liang G; Dillmann U; Rubens R; Kell S; Gupta S
    Parkinsonism Relat Disord; 2014 Dec; 20(12):1335-40. PubMed ID: 25306200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of orally dissolving carbidopa/levodopa (Parcopa) to conventional oral carbidopa/levodopa: A single-dose, double-blind, double-dummy, placebo-controlled, crossover trial.
    Ondo WG; Shinawi L; Moore S
    Mov Disord; 2010 Dec; 25(16):2724-7. PubMed ID: 20925074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Direct switch from conventional levodopa to stalevo (levodopa/carbidopa/entacapone) improves quality of life in Parkinson's disease: results of an open-label clinical study].
    Litvinenko IV; Odinak MM; Mogil'naia VI; Sologub OS; Sakharovskaia AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(1):51-4. PubMed ID: 19156087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of soybean ingestion on pharmacokinetics of levodopa and motor symptoms of Parkinson's disease--In relation to the effects of Mucuna pruriens.
    Nagashima Y; Kondo T; Sakata M; Koh J; Ito H
    J Neurol Sci; 2016 Feb; 361():229-34. PubMed ID: 26810548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous infusion of levodopa-carbidopa intestinal gel in Parkinson's disease.
    Guthikonda LN; Lyons KE; Pahwa R
    J Comp Eff Res; 2014 Jul; 3(4):331-3. PubMed ID: 25275230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.